JW (Cayman) Therapeutics Co (HKSE:02126) Short-Term Debt & Capital Lease Obligation : HK$132.4 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. JW (Cayman) Therapeutics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$132.4 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. JW (Cayman) Therapeutics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$216.3 Mil.

JW (Cayman) Therapeutics Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Short-Term Debt & Capital Lease Obligation Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

11.23

12.90

24.72

170.75

132.35

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial						24.72	26.19	170.75	248.54	132.35

JW (Cayman) Therapeutics Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

JW (Cayman) Therapeutics Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

JWCTF:USA

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

Executives

Li Dan	2202 Interest of your spouse
Li Yiping James	2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd.	2501 Other
Bristol-myers Squibb Company	2201 Interest of corporation controlled by you
Celgene Corporation	2201 Interest of corporation controlled by you
Juno Therapeutics, Inc.	2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd.	2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines